Campath targets CD52, a marker present on other mobile lines besides B-cells, a actuality which makes Campath not quite as certain as Rituxan or HuMax-CD20, causing much more "collateral hurt" from Campath...
The Verdict
ClassificationUnsure
ConfidenceMedium confidence
Analyzedtext, image
ImageLikely AI
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/90915949-5202-4f0a-a73e-a0413bc62902)